{ "company": "Agilent Technologies", "ticker": "A", "period": { "from": "2026-02-27", "to": "2026-03-29", "days": 30 }, "sentiment_breakdown": { "positive": 40, "negative": 13, "neutral": 36 }, "synthesis": { "executive_summary": "**Executive Summary: Agilent Technologies (A) Sentiment Analysis**\n\nDuring the period of February 27 to March 29, 2026, sentiment analysis for Agilent Technologies (A) indicates a predominantly positive, yet mixed, landscape. Out of 89 monitored items, 40 (44.9%) were classified as positive, 13 (14.6%) as negative, and 36 (40.4%) as neutral. The primary positive sentiment drivers were related to insider activity, specifically director stock awards and beneficial ownership changes, signaling confidence in the company's outlook. Conversely, the most notable negative sentiment stemmed from reports detailing Agilent's stock underperformance relative to its competitors, despite recording daily gains.\n\nThe most significant positive events included multiple Form 4 filings detailing director Judy L. Brown's beneficial ownership changes and Otis W. Brawley receiving vested stock awards. These insider transactions are generally interpreted as a positive signal, aligning management interests with shareholder value. On the negative side, a key event highlighted Agilent's stock underperforming its peers on March 24, 2026, despite the stock itself experiencing daily gains. This suggests market concerns regarding Agilent's relative competitive positioning within its sector. Overall, while insider confidence remains a positive factor, competitive stock performance warrants continued monitoring.", "key_findings": [ "✓ Hyrule ATV — The Best All‑Around 4WD Utility Vehicle Powered by Improved FESCA and the QLW Frame", "✓ Agilent Technologies | 4: Statement of changes in beneficial ownership of securities-Director Brown Judy L", "✓ 2 weeks after going live with the premium tier, and I have 19 paying users and a user inspired UI improvement.", "✗ Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer.", "✗ A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanisms.", "✗ Why seems everyone hate the Gen 2 Mjolnir?" ], "overall_sentiment": "positive" }, "top_positive": [ { "title": "Hyrule ATV — The Best All‑Around 4WD Utility Vehicle Powered by Improved FESCA and the QLW Frame", "date": "2026-03-07", "source": "reddit", "score": 0.807 }, { "title": "Agilent Technologies | 4: Statement of changes in beneficial ownership of securities-Director Brown Judy L", "date": "2026-03-24", "source": "alpha_vantage", "score": 0.767 }, { "title": "2 weeks after going live with the premium tier, and I have 19 paying users and a user inspired UI improvement.", "date": "2026-02-27", "source": "reddit", "score": 0.735 }, { "title": "The Rafale is a supremely versatile multirole fighter, fast, agile, and lethal, able to dominate air, land, and sea missions with unmatched flexibility and cutting-edge technology.", "date": "2026-03-18", "source": "reddit", "score": 0.71 }, { "title": "Agilent (NYSE: A) director Otis Brawley granted vested stock awards", "date": "2026-03-23", "source": "alpha_vantage", "score": 0.681 }, { "title": "Agilent Technologies, Inc. Receives FDA Approval For PD-L1 IHC 22C3 PharmDx In Esophageal Or Gastroesophageal Junction Carcinoma", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.677 }, { "title": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.677 }, { "title": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma", "date": "2026-03-26", "source": "alpha_vantage", "score": 0.677 }, { "title": "Agilent (NYSE: A) director Judy Brown granted 2,158 fully vested shares", "date": "2026-03-23", "source": "alpha_vantage", "score": 0.657 }, { "title": "Agilent (NYSE: A) director granted 2,158 fully vested common shares", "date": "2026-03-23", "source": "alpha_vantage", "score": 0.655 } ], "top_negative": [ { "title": "Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.743 }, { "title": "A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanisms.", "date": "2026-03-29", "source": "pubmed", "score": -0.621 }, { "title": "Why seems everyone hate the Gen 2 Mjolnir?", "date": "2026-02-27", "source": "reddit", "score": -0.572 }, { "title": "Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience.", "date": "2026 Mar 1", "source": "pubmed", "score": -0.527 }, { "title": "Agilent Technologies Inc. stock underperforms Tuesday when compared to competitors despite daily gains", "date": "2026-03-24", "source": "alpha_vantage", "score": -0.458 }, { "title": "FDA approves Agilent test to match some esophageal cancer patients to Keytruda", "date": "2026-03-26", "source": "alpha_vantage", "score": -0.402 }, { "title": "Riverbridge Partners LLC Cuts Stock Holdings in Danaher Corporation $DHR", "date": "2026-03-27", "source": "alpha_vantage", "score": -0.296 }, { "title": "Danaher Corp. stock faces pressure amid life sciences slowdown and biotech funding crunch", "date": "2026-03-24", "source": "alpha_vantage", "score": -0.296 }, { "title": "3+ yrs Product Manager. 150–200 applications in ~3 months, no calls. Resume + positioning feedback?", "date": "2026-03-12", "source": "reddit", "score": -0.296 }, { "title": "Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.", "date": "2026-03-29", "source": "pubmed", "score": -0.202 } ], "raw_data": { "total_items": 89, "items": [ { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-03-20", "url": "https://www.sec.gov/Archives/edgar/data/1090872/000119312526117614/0001193125-26-117614-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "8-K", "title": "8-K - Current report", "date": "2026-03-06", "url": "https://www.sec.gov/Archives/edgar/data/1090872/000119312526096487/0001193125-26-096487-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "sec", "filing_type": "10-Q", "title": "10-Q - Quarterly report [Sections 13 or 15(d)]", "date": "2026-03-03", "url": "https://www.sec.gov/Archives/edgar/data/1090872/000109087226000023/0001090872-26-000023-index.htm", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Merck & Co., Inc. $MRK Shares Sold by Advisors Management Group Inc. ADV", "url": "https://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-shares-sold-by-advisors-management-group-inc-adv-2026-03-29/", "date": "2026-03-29", "summary": "Advisors Management Group Inc. ADV reduced its stake in Merck & Co., Inc. by 15.2% during the fourth quarter, selling 10,482 shares and now holding 58,625 shares valued at $6.17 million. This comes as Merck made a strategic acquisition of Terns Pharmaceuticals for $6.7 billion to bolster its pipeline ahead of Keytruda's patent expiration, a move that has garnered analyst support despite potential challenges like rival bids and a shareholder investigation. Merck also reported strong quarterly ear", "sentiment_score": 0.210623, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.613643, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "There's A Lot To Like About Agilent Technologies' (NYSE:A) Upcoming US$0.255 Dividend", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/theres-a-lot-to-like-about-agilent-technologies-nysea-upcomi/amp", "date": "2026-03-28", "summary": "Agilent Technologies (NYSE:A) is set to pay a US$0.255 dividend, with an ex-dividend date around March 31st. The company boasts a low and conservative payout ratio of 22% of its income and 28% of its free cash flow, indicating the dividend is sustainable. With earnings per share growing at 14% annually over the last five years and a 9.8% average annual increase in dividends over 10 years, Agilent Technologies presents an attractive combination of growth and shareholder returns.", "sentiment_score": 0.538568, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "MaxCyte Appoints New Chief Financial Officer Ahuja", "url": "https://www.tipranks.com/news/company-announcements/maxcyte-appoints-new-chief-financial-officer-ahuja", "date": "2026-03-27", "summary": "MaxCyte has appointed Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Ahuja brings over two decades of financial experience from Agilent Technologies, signaling MaxCyte's focus on strengthening its financial operations and investor relations. His compensation package includes a $450,000 base salary, a target cash bonus, and substantial equity awards, with the company's stock currently holding a \"Sell\" recommendation from Spark, TipRanks’ AI Analyst, due to weak financ", "sentiment_score": 0.327559, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.602338, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Agilent Technologies (A) to acquire Biocare Medical for $950M", "url": "https://www.msn.com/en-us/health/other/agilent-technologies-a-to-acquire-biocare-medical-for-950m/ar-AA1ZiPrj", "date": "2026-03-27", "summary": "Agilent Technologies has announced its intention to acquire Biocare Medical for $950 million. Biocare Medical is a company specializing in cancer research and diagnostics. This acquisition aims to strengthen Agilent's portfolio in the pathology and diagnostics market.", "sentiment_score": 0.390312, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock outperforms competitors despite losses on the day", "url": "https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-outperforms-competitors-despite-losses-on-the-day-7264dae7-99becdb146ed?gaa_at=eafs&gaa_n=AWEtsqernVRcv_wJk3arnJxRD69ss58OD7kyFQb3-afZ6GbnD8YpYeJ5DR2u&gaa_ts=69c77a8e&gaa_sig=De1azcmE13M-HDtF3Ths-Lcjni4UD7VX__NiCjql9oXAg9K7j615gvMZ0jwIKkoiIel8wbtfo7zuLEL-TcrWFw%3D%3D", "date": "2026-03-27", "summary": "Agilent Technologies Inc.'s stock (A) dropped 2.86% to $110.24, experiencing losses on a generally negative trading day where the S&P 500 and Dow Jones Industrial Average also fell. Despite this, the stock showed relative outperformance compared to its competitors. Agilent Technologies Inc. is currently trading 31.22% below its 52-week high of $160.27, achieved on November 25th.", "sentiment_score": 0.041445, "sentiment_label": "Neutral", "relevance_score": 0.34973, "sentiment": { "label": "positive", "score": 0.309, "confidence": 0.31 } }, { "source": "alpha_vantage", "title": "There's A Lot To Like About Agilent Technologies' (NYSE:A) Upcoming US$0.255 Dividend", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-a/agilent-technologies/news/theres-a-lot-to-like-about-agilent-technologies-nysea-upcomi", "date": "2026-03-27", "summary": "Agilent Technologies (NYSE:A) is set to pay a US$0.255 dividend, offering a trailing yield of 0.9%. The company demonstrates strong dividend sustainability with a low payout ratio of 22% of income and 28% of free cash flow, alongside robust earnings per share growth of 14% annually over the last five years. These factors, combined with a decade of consistent dividend growth, suggest an attractive investment for dividend-focused shareholders.", "sentiment_score": 0.603471, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock: Precision instruments leader navigating life sciences and diagnosti", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-precision-instruments-leader-navigating/69004318", "date": "2026-03-27", "summary": "Agilent Technologies Inc. is a leader in precision instrumentation for life sciences, diagnostics, and applied chemical markets, providing critical tools for pharmaceuticals, biotech, and environmental testing. The company's business model is diversified across three primary segments, focusing on innovation, global expansion, and a strong competitive moat. It offers North American investors exposure to high-growth areas within healthcare, balanced by recurring revenues and a commitment to capita", "sentiment_score": 0.46194, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Riverbridge Partners LLC Cuts Stock Holdings in Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-riverbridge-partners-llc-cuts-stock-holdings-in-danaher-corporation-dhr-2026-03-27/", "date": "2026-03-27", "summary": "Riverbridge Partners LLC has reduced its stake in Danaher Corporation by 3.9% in the fourth quarter, selling 9,641 shares and now holding 240,606 shares valued at $55.08 million. Despite this trimming, institutional investors collectively own approximately 79.05% of Danaher's stock. The company recently exceeded Q4 earnings estimates with $2.23 EPS and $6.84 billion in revenue and increased its quarterly dividend to $0.40, while analysts maintain a \"Moderate Buy\" consensus rating and a target pr", "sentiment_score": 0.068892, "sentiment_label": "Neutral", "relevance_score": 0.526463, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Waters Corp Stock: Analytical Instruments Leader Faces Growth Challenges Amid Sector Tailwinds", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/waters-corp-stock-analytical-instruments-leader-faces-growth-challenges/69003163", "date": "2026-03-27", "summary": "Waters Corp (NYSE:WAT), a leader in analytical workflow solutions, faces growth challenges despite tailwinds in the scientific instruments sector. The company specializes in liquid chromatography and mass spectrometry, serving pharmaceutical, biotech, and environmental testing markets. While institutional investors like Vanguard maintain positions, recent performance has been mixed, with modest share declines and analyst ratings leaning towards a \"Moderate Buy.\"", "sentiment_score": 0.14496, "sentiment_label": "Neutral", "relevance_score": 0.639721, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Agilent Technologies, Inc. Receives FDA Approval For PD-L1 IHC 22C3 PharmDx In Esophageal Or Gastroesophageal Junction Carcinoma", "url": "https://www.marketscreener.com/news/agilent-technologies-inc-receives-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-esophageal-or-gastroe-ce7e51dbda88f427", "date": "2026-03-27", "summary": "Agilent Technologies Inc. (NYSE:A) has received FDA approval for its PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic. This diagnostic will assist in identifying patients with esophageal or gastroesophageal junction carcinoma who may be suitable for treatment with Merck's KEYTRUDA (pembrolizumab). This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx, expanding its use to several other cancers.", "sentiment_score": 0.734844, "sentiment_label": "Bullish", "relevance_score": 0.972139, "sentiment": { "label": "positive", "score": 0.677, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma", "url": "https://www.biospace.com/press-releases/agilent-receives-fda-approval-for-pd-l1-ihc-22c3-pharmdx-in-esophageal-or-gastroesophageal-junction-gej-carcinoma", "date": "2026-03-27", "summary": "Agilent Technologies Inc. announced that its PD-L1 IHC 22C3 pharmDx, Code SK006, has received FDA approval as a companion diagnostic for patients with esophageal or gastroesophageal junction (GEJ) carcinoma. This diagnostic identifies patients eligible for treatment with Merck’s KEYTRUDA® (pembrolizumab). This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx, reinforcing Agilent's role in precision medicine for anti-PD-1 therapies.", "sentiment_score": 0.537739, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.677, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "Whole Genome Sequencing Market Key Aspects, Benefits, and Challenges 2026-2033 | Major Companies - Illumina; Inc., QIAGEN, Agilent Technologies, PerkinElmer Genomics", "url": "https://www.openpr.com/news/4442890/whole-genome-sequencing-market-key-aspects-benefits", "date": "2026-03-27", "summary": "The global Whole Genome Sequencing (WGS) Market is projected to grow at a CAGR of 15% from 2024 to 2031, driven by rising demand for precision medicine, technological advancements, and decreasing costs. Key players include Illumina, Thermo Fisher Scientific, QIAGEN, and Agilent Technologies, with significant recent developments in the U.S. and Japan focusing on AI integration and expanded clinical adoption. The market covers instruments, consumables, and services across diagnostics, drug discove", "sentiment_score": 0.324326, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.730086, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Is It Time To Reassess Thermo Fisher Scientific (TMO) After Recent Share Price Weakness?", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/is-it-time-to-reassess-thermo-fisher-scientific-tmo-after-re", "date": "2026-03-26", "summary": "This article reassesses Thermo Fisher Scientific (TMO) following recent share price weakness. Using a Discounted Cash Flow analysis, the stock is estimated to be roughly 4.3% undervalued, while its P/E ratio suggests it is undervalued compared to industry and peer averages. The article encourages investors to use Simply Wall St's \"Narratives\" feature to align valuation with their personal investment outlook.", "sentiment_score": 0.137453, "sentiment_label": "Neutral", "relevance_score": 0.560411, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "FDA approves Agilent test to match some esophageal cancer patients to Keytruda", "url": "https://www.stocktitan.net/news/A/agilent-receives-fda-approval-for-pd-l1-ihc-22c3-pharm-dx-in-2spln2dktuzv.html", "date": "2026-03-26", "summary": "Agilent Technologies announced FDA approval for its PD-L1 IHC 22C3 pharmDx, a companion diagnostic designed to identify patients with esophageal or gastroesophageal junction (GEJ) carcinoma eligible for treatment with Merck's immunotherapy, KEYTRUDA. This approval marks the eighth such indication for this test, reinforcing Agilent's role in precision medicine for various cancers. The diagnostic identifies patients whose tumors express PD-L1 (Combined Positive Score ≥ 1), crucial for targeted the", "sentiment_score": 0.708861, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma", "url": "https://www.businesswire.com/news/home/20260326909115/en/Agilent-Receives-FDA-Approval-for-PD-L1-IHC-22C3-pharmDx-in-Esophageal-or-Gastroesophageal-Junction-GEJ-Carcinoma", "date": "2026-03-26", "summary": "Agilent Technologies Inc. has announced FDA approval for its PD-L1 IHC 22C3 pharmDx as a companion diagnostic. This test identifies patients with esophageal or gastroesophageal junction (GEJ) carcinoma who may benefit from treatment with Merck's KEYTRUDA. This approval is the eighth FDA-approved companion diagnostic indication for the test with KEYTRUDA, highlighting Agilent's role in advancing precision medicine in oncology.", "sentiment_score": 0.808196, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.677, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock climbs on launch of advanced chromatography solutions boosting life sciences research", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-climbs-on-launch-of-advanced/68993869", "date": "2026-03-26", "summary": "Agilent Technologies Inc. (US00846U1016) stock has risen following the launch of new chromatography solutions designed to accelerate life sciences research and drug discovery. The company's innovations address key challenges in biotechnology R&D, positioning Agilent as a leader in analytical instrumentation and attracting investor interest. This development comes amid renewed investor appetite for life sciences enablers and aims to expand Agilent's market share in high-growth areas.", "sentiment_score": 0.448972, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "Jeffrey Li Sells 2,000 Shares of Keysight Technologies (NYSE:KEYS) Stock", "url": "https://www.marketbeat.com/instant-alerts/jeffrey-li-sells-2000-shares-of-keysight-technologies-nysekeys-stock-2026-03-26/", "date": "2026-03-26", "summary": "Jeffrey Li, SVP at Keysight Technologies, sold 2,000 shares of company stock for approximately $594,380 on March 24, reducing his stake by 5.48%. The sale was disclosed amidst strong financial performance from Keysight, which recently exceeded quarterly estimates, reported significant revenue growth, and received positive analyst ratings with a \"Moderate Buy\" consensus. The company is actively expanding its manufacturing and investing in AI/HPC and automotive test solutions, reflecting continued", "sentiment_score": 0.144922, "sentiment_label": "Neutral", "relevance_score": 0.639823, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Q4 Research Tools & Consumables Earnings: Bio-Techne (NASDAQ:TECH) Earns Top Marks", "url": "https://stockstory.org/us/stocks/nasdaq/tech/news/earnings/q4-research-tools-and-consumables-earnings-bio-techne-nasdaqtech-earns-top-marks", "date": "2026-03-26", "summary": "Bio-Techne reported strong Q4 results, exceeding analyst expectations for revenue, though its stock saw an 18.5% decline post-reporting. The broader research tools & consumables sector had a satisfactory Q4, with revenues beating estimates by 1.2%, but share prices for many companies in the sector declined significantly. The article also reviews Q4 performance for other companies like Revvity, Mettler-Toledo, Sotera Health Company, and Agilent, highlighting varying results and market reactions a", "sentiment_score": -0.131594, "sentiment_label": "Neutral", "relevance_score": 0.622385, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock climbs amid new chromatography solutions launch signaling life sciences expansion", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-climbs-amid-new-chromatography-solutions/68989819", "date": "2026-03-26", "summary": "Agilent Technologies Inc. (NYSE: A) stock rose after the company launched new chromatography solutions, enhancing its offerings for the life sciences sector. These advanced tools, designed for complex biomolecule analysis, are expected to accelerate drug discovery and boost Agilent's market share in biopharma and diagnostics. The move aligns with growing demand for precise analytical instruments and is seen as a strategic push into high-growth markets, attracting investor confidence.", "sentiment_score": 0.425662, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock rises on advanced chromatography solutions launch boosting lab effic", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-rises-on-advanced-chromatography-solutions/68979233", "date": "2026-03-25", "summary": "Agilent Technologies Inc. has launched new chromatography solutions aimed at enhancing lab efficiency in pharmaceutical and biotech research, integrating AI-driven data processing for faster analysis. This innovation positions Agilent for growth in high-margin R&D markets, attracting investor interest with its stock trading around 111 USD on the NYSE. The company's strategic focus on critical needs like trace impurity detection and strong positioning in the expanding life sciences sector contrib", "sentiment_score": 0.039326, "sentiment_label": "Neutral", "relevance_score": 0.322898, "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock underperforms Wednesday when compared to competitors", "url": "https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-underperforms-wednesday-when-compared-to-competitors-9c6abbcb-638f58145dd7?gaa_at=eafs&gaa_n=AWEtsqcRU401gkswQkC7TJ5d8rE9zoRiUMtIsflMQkF9Dd1S23OrUOQCGoLH&gaa_ts=69c4a655&gaa_sig=DHgyOLpXTnDVU3f78OEnZ5OAW_XDS64WuQptPy4tCVxhf02WmpfaoVl8lyEpCDH3_izd3FmqGLP8LVCQm2u4kw%3D%3D", "date": "2026-03-25", "summary": "Agilent Technologies Inc. (A) saw its stock decline by 1.07% to $112.98 on Wednesday, despite a positive trading session for the broader market. This drop ended a two-day winning streak for the company's shares. The S&P 500 Index rose 0.54%, and the Dow Jones Industrial Average gained 0.66% on the same day.", "sentiment_score": -0.321208, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.962441, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Pensionfund Sabic Buys New Position in Agilent Technologies, Inc. $A", "url": "https://www.marketbeat.com/instant-alerts/filing-pensionfund-sabic-buys-new-position-in-agilent-technologies-inc-a-2026-03-25/", "date": "2026-03-25", "summary": "Pensionfund Sabic initiated a new position in Agilent Technologies (NYSE:A) during Q4, purchasing 9,500 shares valued at approximately $1.29 million. Agilent reported Q1 EPS of $1.36 and revenue of $1.80 billion, while also declaring a quarterly dividend of $0.255. The company currently holds a \"Moderate Buy\" consensus rating from MarketBeat with a target price of $161.20.", "sentiment_score": 0.344913, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Pensionfund Sabic Purchases Shares of 7,500 Keysight Technologies Inc. $KEYS", "url": "https://www.marketbeat.com/instant-alerts/filing-pensionfund-sabic-purchases-shares-of-7500-keysight-technologies-inc-keys-2026-03-25/", "date": "2026-03-25", "summary": "Pensionfund Sabic has acquired a new position in Keysight Technologies Inc. (NYSE:KEYS) by purchasing 7,500 shares valued at approximately $1.524 million in the fourth quarter. This move comes as research firms have upgraded Keysight and raised price targets, reflecting a \"Moderate Buy\" consensus. Despite insider sales totaling over $10 million in the last quarter, Keysight reported strong earnings, beating revenue and EPS expectations.", "sentiment_score": 0.115036, "sentiment_label": "Neutral", "relevance_score": 0.637918, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "U.S. Compound Management Market Is Going to Boom | Thermo Fisher", "url": "https://www.openpr.com/news/4439576/u-s-compound-management-market-is-going-to-boom-thermo-fisher", "date": "2026-03-25", "summary": "Coherent Market Insights has published a report on the \"U.S. Compound Management Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033\". The report provides an in-depth analysis of market performance, competition, regional distribution, and growth potential, making it a valuable tool for entrepreneurs, investors, and business strategists. It also includes key market players, segmentation by end-user, research methodology, and strategic points of analysis.", "sentiment_score": 0.728003, "sentiment_label": "Bullish", "relevance_score": 0.733409, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "DAVENPORT & Co LLC Lowers Holdings in Danaher Corporation $DHR", "url": "https://www.marketbeat.com/instant-alerts/filing-davenport-co-llc-lowers-holdings-in-danaher-corporation-dhr-2026-03-25/", "date": "2026-03-25", "summary": "DAVENPORT & Co LLC reduced its stake in Danaher Corporation (NYSE:DHR) by 1.1% in the fourth quarter, holding 666,096 shares valued at $152.75 million. Other institutional investors also adjusted their positions, and Danaher currently has a \"Moderate Buy\" analyst rating with an average target price of $253.55. The company recently reported strong quarterly earnings, exceeding analyst estimates, and increased its quarterly dividend to $0.40 per share.", "sentiment_score": 0.023835, "sentiment_label": "Neutral", "relevance_score": 0.589619, "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Danaher Corp. stock faces pressure amid life sciences slowdown and biotech funding crunch", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/danaher-corp-stock-faces-pressure-amid-life-sciences-slowdown-and-biotech/68979030", "date": "2026-03-24", "summary": "Danaher Corp. (NYSE: DHR) is experiencing stock pressure due to a slowdown in the life sciences sector and a crunch in biotech funding, evidenced by weaker demand for biotechnology tools and diagnostics. Investors are closely monitoring Q1 guidance as operating margins compress, with analysts highlighting Danaher's role as a bellwether for innovation spending. The company's diversified portfolio and strong balance sheet position it for long-term recovery, despite current challenges in organic gr", "sentiment_score": -0.145728, "sentiment_label": "Neutral", "relevance_score": 0.561447, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "United Air starts record fleet upgrade with plush new seats", "url": "https://www.chicagotribune.com/2026/03/24/united-air-seat-upgrade/", "date": "2026-03-24", "summary": "United Airlines is undertaking its largest fleet modernization, adding over 250 new aircraft by April 2028, including Airbus A321XLR and Boeing 787-9 models with upgraded premium seating. This initiative aims to enhance the airline's premium travel strategy and expand routes, especially to European and South American cities. CEO Scott Kirby acknowledges potential ticket price increases due to rising fuel costs but asserts the airline's strength to navigate challenges without deferring investment", "sentiment_score": 0.045689, "sentiment_label": "Neutral", "relevance_score": 0.570891, "sentiment": { "label": "positive", "score": 0.621, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock rises on advanced chromatography solutions launch boosting life scie", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-inc-stock-rises-on-advanced-chromatography-solutions/68977773", "date": "2026-03-24", "summary": "Agilent Technologies Inc. (A) has launched advanced chromatography solutions aimed at improving lab efficiency in pharmaceutical research and quality control. This move comes amidst surging biotech investments and heightened demand in the pharma and biotech sectors, positioning Agilent for sustained revenue growth. The stock is trading around $111 on the NYSE, reflecting investor confidence in the company's innovation and its strategic fit within the booming life sciences market.", "sentiment_score": 0.485602, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.625, "confidence": 0.62 } }, { "source": "alpha_vantage", "title": "Agilent Technologies | 4: Statement of changes in beneficial ownership of securities-Director Brown Judy L", "url": "https://www.moomoo.com/news/notice/306719884/agilent-technologies-4-statement-of-changes-in-beneficial-ownership-of", "date": "2026-03-24", "summary": "This document is a statement of changes in beneficial ownership of securities for Director Judy L. Brown of Agilent Technologies, as detailed in a Form 4 filing. It indicates transactions affecting her ownership of company stock.", "sentiment_score": 0.04879, "sentiment_label": "Neutral", "relevance_score": 0.307381, "sentiment": { "label": "positive", "score": 0.767, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Inc. stock underperforms Tuesday when compared to competitors despite daily gains", "url": "https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-underperforms-tuesday-when-compared-to-competitors-despite-daily-gains-eb6d8b5d-0a28f197880f?gaa_at=eafs&gaa_n=AWEtsqetnz3mpF0lQhX3IvCrBm9WY29wAauOC2t6HWWIbisELYYC-9iF1Jo8&gaa_ts=69c3fd95&gaa_sig=kmngcH0A2Vim54kES_WZjV85TdY7R1ZXICpfic1jYKKwgY3BuTLbNQeBFqUn7UUnEpr-6VnSIgCOLRL_oI45nA%3D%3D", "date": "2026-03-24", "summary": "Agilent Technologies Inc. (A) stock gained 1.95% to $114.20 on Tuesday, despite a broader market downturn where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for Agilent's stock. However, it underperformed compared to its competitors, even with the daily increase.", "sentiment_score": -0.18795, "sentiment_label": "Somewhat-Bearish", "relevance_score": 0.963382, "sentiment": { "label": "negative", "score": -0.458, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "Bullish Move: Sue Rataj Shows Confidence, Acquires $241K In Agilent Technologies Stock", "url": "https://www.benzinga.com/insights/news/26/03/51434750/bullish-move-sue-rataj-shows-confidence-acquires-241k-in-agilent-technologies-stock", "date": "2026-03-24", "summary": "Sue Rataj, a Director at Agilent Technologies, recently purchased 2,158 shares of the company's stock for $241,156, indicating bullish sentiment. The article details Agilent's financial performance, including a 6.96% revenue growth, a gross margin of 52.61%, and a debt-to-equity ratio of 0.49. It also touches on valuation metrics and the significance of insider transactions for investors.", "sentiment_score": 0.521018, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Eye On Growth: Dr. Scangos Adds $359K Of Agilent Technologies Stock To Portfolio", "url": "https://www.benzinga.com/insights/news/26/03/51434757/eye-on-growth-dr-scangos-adds-359k-of-agilent-technologies-stock-to-portfolio", "date": "2026-03-24", "summary": "Dr. Scangos, a Director at Agilent Technologies (NYSE: A), recently purchased 3,215 shares of the company's stock for $359,276, as disclosed in an SEC filing on March 23. This insider transaction signals confidence in Agilent Technologies's potential. The article also provides a detailed financial overview, highlighting the company's profitability, debt management, and valuation metrics.", "sentiment_score": 0.481531, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Director Of Agilent Technologies Purchased $340K In Stock", "url": "https://www.benzinga.com/insights/news/26/03/51434753/director-of-agilent-technologies-purchased-340k-in-stock", "date": "2026-03-24", "summary": "A director at Agilent Technologies (NYSE: A), Otis W Brawley, recently purchased $340,390 worth of the company's stock, demonstrating confidence in its potential. Agilent Technologies, a leading life science and diagnostic firm, has shown strong revenue growth and healthy debt management, though its EPS is currently below the industry average. Insider transactions, like this significant buy, are often seen as a positive indicator for a stock's future performance.", "sentiment_score": 0.361395, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Board Member At Agilent Technologies Buys $241K of Stock", "url": "https://www.benzinga.com/insights/news/26/03/51434758/board-member-at-agilent-technologies-buys-241k-of-stock", "date": "2026-03-24", "summary": "DOW WILSON, a Board Member at Agilent Technologies (NYSE: A), recently purchased 2,158 shares of the company's stock for $241,156. This insider transaction signals confidence in the company's growth potential. Agilent Technologies, a life science and diagnostic firm, reported positive revenue growth but faced challenges in some key profitability metrics compared to its peers.", "sentiment_score": 0.307464, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Agilent Technologies (A) to Acquire Biocare Medical for $950M", "url": "https://www.insidermonkey.com/blog/agilent-technologies-a-to-acquire-biocare-medical-for-950m-1723126/", "date": "2026-03-24", "summary": "Agilent Technologies (NYSE:A) announced its definitive agreement to acquire Biocare Medical for $950 million in an all-cash deal, aiming to strengthen its position in cancer diagnostics and clinical research. Biocare's high-growth portfolio of immunohistochemistry antibodies and reagents is expected to be immediately accretive to Agilent's revenue and margins. Additionally, Agilent launched Agilent Advanced Therapeutics, a unified Contract Development and Manufacturing Organization (CDMO) for ol", "sentiment_score": 0.449419, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "A SEC Filings - Agilent Technologies Inc 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/A/page-8.html", "date": "2026-03-24", "summary": "This page on Stock Titan provides comprehensive access to Agilent Technologies Inc.'s official SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading information. It details how Agilent uses these filings to report financial performance, governance changes, and executive compensation, often including non-GAAP financial measures for analytical purposes. The platform also offers AI-powered summaries of key filing details, such as recent insider transactions by Director Judy", "sentiment_score": 0.146951, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Faces Mixed Technical Signals Amid Valuation Adjustments", "url": "https://www.marketsmojo.com/news/stock-recommendation/agilent-technologies-downgraded-from-buy-to-hold-amid-bearish-trends-and-profit-decline-3908387", "date": "2026-03-24", "summary": "Agilent Technologies, Inc. is experiencing mixed technical signals and valuation adjustments. While the company demonstrates a strong return on capital employed (ROCE) of 18.80%, it faces challenges with declining profits and bearish technical indicators. Its valuation score has shifted from \"very attractive\" to \"attractive.\"", "sentiment_score": -0.297655, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "SG Americas Securities LLC Has $109.97 Million Position in Agilent Technologies, Inc. $A", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-has-10997-million-position-in-agilent-technologies-inc-a-2026-03-24/", "date": "2026-03-24", "summary": "SG Americas Securities LLC significantly increased its stake in Agilent Technologies (NYSE:A) by 3,091.1% in the fourth quarter, now holding 808,215 shares valued at $109.97 million. This comes as Agilent reported Q4 EPS of $1.36 and revenue of $1.80 billion, while also declaring a quarterly dividend of $0.255. Institutional investors collectively own about 87.4% of the medical research company's stock, and analysts currently rate it a \"Moderate Buy.\"", "sentiment_score": 0.173626, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "US Multiomic Market Set to Boom Rapidly, Witnessing Strong", "url": "https://www.openpr.com/news/4437722/us-multiomic-market-set-to-boom-rapidly-witnessing-strong", "date": "2026-03-24", "summary": "Coherent Market Insights has released a new research study on the Global \"US Multiomic Market\" forecasting strong growth through 2033. The report segments the market by type (Genomics, Proteomics, Metabolomics) and applications (Precision Medicine, Drug Discovery, Clinical Research), and provides competitive and regional analysis. Key players include Illumina Inc., Thermo Fisher Scientific Inc., and Agilent Technologies Inc.", "sentiment_score": 0.328078, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.727962, "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "A SEC Filings - Agilent Technologies Inc 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/A/page-6.html", "date": "2026-03-24", "summary": "This page provides a comprehensive resource for Agilent Technologies Inc. (NYSE: A) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights recent insider transactions, such as RSU tax share surrenders and stock option exercises, and details the appointment and compensation package of the new CFO. The platform offers AI-powered summaries of these regulatory documents to assist investors.", "sentiment_score": -0.038345, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "A SEC Filings - Agilent Technologies Inc 10-K, 10-Q, 8-K Forms", "url": "https://www.stocktitan.net/sec-filings/A/page-3.html", "date": "2026-03-24", "summary": "This page provides access to Agilent Technologies (NYSE: A) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings detailing an amendment to insider holdings, the company's global lab and diagnostic operations, and several insider stock sales and tax-related share surrenders. Stock Titan offers AI-powered summaries of these filings to help investors understand key points like leadership changes", "sentiment_score": 0.015589, "sentiment_label": "Neutral", "relevance_score": 0.328174, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Agilent Technologies | 4: Statement of changes in beneficial ownership of securities-Director Podolsky Daniel K", "url": "https://www.moomoo.com/news/notice/306719980/agilent-technologies-4-statement-of-changes-in-beneficial-ownership-of", "date": "2026-03-23", "summary": "This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Daniel K. Podolsky, a Director at Agilent Technologies. It details changes in his ownership of company securities.", "sentiment_score": 0.019407, "sentiment_label": "Neutral", "relevance_score": 0.344336, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Agilent Technologies | 4: Statement of changes in beneficial ownership of securities-Director WILSON DOW R", "url": "https://www.moomoo.com/news/notice/306720229/agilent-technologies-4-statement-of-changes-in-beneficial-ownership-of", "date": "2026-03-23", "summary": "This article is a statement of changes in beneficial ownership of securities for Director WILSON DOW R at Agilent Technologies. It is a mandatory disclosure document related to stock transactions involving company insiders.", "sentiment_score": 0.047734, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Agilent (NYSE: A) director granted 2,158 fully vested common shares", "url": "https://www.stocktitan.net/sec-filings/A/form-4-agilent-technologies-inc-insider-trading-activity-d34fca44b4a7.html", "date": "2026-03-23", "summary": "Agilent Technologies director Sue H. Rataj was granted 2,158 fully vested shares of common stock as compensation for her service. The shares were awarded on March 19, 2026, at a reference price of $111.75 per share, increasing her direct holdings to 23,617 shares. This transaction was reported in an SEC Form 4 filing.", "sentiment_score": 0.029868, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.655, "confidence": 0.65 } }, { "source": "alpha_vantage", "title": "Agilent (NYSE: A) director Wilson Dow reports fully vested stock grant", "url": "https://www.stocktitan.net/sec-filings/A/form-4-agilent-technologies-inc-insider-trading-activity-4627a902e286.html", "date": "2026-03-23", "summary": "Agilent Technologies director Wilson Dow reported a fully vested stock grant of 2,158 shares of common stock on March 19, 2026, at a reference price of $111.75 per share. This compensation-related acquisition increased his direct holdings to 20,368.606 shares. Additionally, 144.124 shares were acquired through the company’s dividend reinvestment plan and deferred.", "sentiment_score": 0.004014, "sentiment_label": "Neutral", "relevance_score": 0.300744, "sentiment": { "label": "positive", "score": 0.566, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Agilent Technologies Launches Advanced Chromatography Solutions Enhancing Precision in Drug Development", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/agilent-technologies-launches-advanced-chromatography-solutions-enhancing/68970279", "date": "2026-03-23", "summary": "Agilent Technologies has introduced advanced chromatography solutions, including new HPLC and GC systems, designed to enhance precision and efficiency in drug development, particularly for antibody-drug conjugates (ADCs). These innovations reduce processing times by up to 30% and lower five-year ownership costs by 25%, strengthening Agilent's position in the premium life sciences segment. The company's strategic focus on R&D, recurring service revenues, and global market penetration aims to secu", "sentiment_score": 0.483812, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.402, "confidence": 0.4 } }, { "source": "alpha_vantage", "title": "Agilent (NYSE: A) director Otis Brawley granted vested stock awards", "url": "https://www.stocktitan.net/sec-filings/A/form-4-agilent-technologies-inc-insider-trading-activity-a6ceafe4be57.html", "date": "2026-03-23", "summary": "Agilent Technologies director Otis W. Brawley received two awards of common stock on March 19, 2026, totaling 3,046 shares, as compensation grants. These non-employee director awards, valued at $111.75 per share, were fully vested upon grant. Brawley elected to defer the receipt of these shares into a company-sponsored deferral account, bringing his total reported holdings to 13,873.623 shares of Agilent common stock.", "sentiment_score": 0.027025, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.681, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "Director George Scangos gets 3,215 Agilent (NYSE: A) shares", "url": "https://www.stocktitan.net/sec-filings/A/form-4-agilent-technologies-inc-insider-trading-activity-f849bb08fcce.html", "date": "2026-03-23", "summary": "Agilent (NYSE: A) director George A. Scangos reported receiving two equity awards of common stock on March 19, 2026, totaling 3,215 shares at a reference price of $111.75 per share. These awards, along with 148.973 shares from a dividend reinvestment plan, are fully vested but deferred into an Agilent compensation plan for non-employee directors. After these transactions, Scangos holds over 23,857 Agilent shares directly in deferred accounts and an additional 17,893 shares indirectly through a f", "sentiment_score": 0.032443, "sentiment_label": "Neutral", "relevance_score": 0.328999, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Agilent (NYSE: A) director granted shares and withholds stock for taxes", "url": "https://www.stocktitan.net/sec-filings/A/form-4-agilent-technologies-inc-insider-trading-activity-612fe62fc458.html", "date": "2026-03-23", "summary": "Agilent Technologies director Koh Boon Hwee received an award of 2,158 shares of common stock valued at $111.75 per share as compensation, which vested immediately. He then surrendered 648 shares back to Agilent to cover tax liabilities associated with this award and the vesting of restricted stock units. After these transactions, and accounting for deferred shares from a dividend reinvestment plan, Koh holds 63,184.351 shares of Agilent common stock.", "sentiment_score": 0.034612, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Agilent (NYSE: A) director Judy Brown granted 2,158 fully vested shares", "url": "https://www.stocktitan.net/sec-filings/A/form-4-agilent-technologies-inc-insider-trading-activity-fefe71b91e3f.html", "date": "2026-03-23", "summary": "Agilent Technologies director Judy L. Brown received an award of 2,158 shares of common stock on March 19, 2026. This award for non-employee directors was valued at $111.75 per share and became fully vested upon grant. Following this transaction, Brown directly owns 3,835 Agilent shares, with the acquisition noted as compensation-related rather than an open-market purchase.", "sentiment_score": 0.102811, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.657, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41888596", "title": "Atlas of one-carbon metabolism in conventional and germ-free mice reveals folate as a key determinant of biochemical pathways.", "authors": "Williams J et al.", "journal": "Nature metabolism", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41888596/", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "pubmed", "pmid": "41875078", "title": "A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanisms.", "authors": "Mamede LD et al.", "journal": "PLoS biology", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41875078/", "sentiment": { "label": "negative", "score": -0.621, "confidence": 0.62 } }, { "source": "pubmed", "pmid": "41858189", "title": "Multiple Heart-Cut Ion-Exchange Chromatography-Reversed-Phase Liquid Chromatography Platform for Online Desalting and Fractionation of Monoclonal Antibody Charge Variants.", "authors": "van der Zon AAM et al.", "journal": "Journal of separation science", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41858189/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41821182", "title": "Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer.", "authors": "Jin X et al.", "journal": "Cancer biology & medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41821182/", "sentiment": { "label": "negative", "score": -0.743, "confidence": 0.74 } }, { "source": "pubmed", "pmid": "41818842", "title": "Feed injection-enabled reversed phase liquid chromatography for simplified analysis of lipophilic drugs and formulations.", "authors": "Foshag D et al.", "journal": "Journal of chromatography. A", "date": "2026 May 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41818842/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41817181", "title": "Emergence of artemisinin-based combination therapy resistance markers in Plasmodium falciparum from the Brazilian tri-border region of the Guiana Shield.", "authors": "Salazar YEAR et al.", "journal": "Antimicrobial agents and chemotherapy", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817181/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41804290", "title": "In Memoriam: The Scientific Legacy of Dr. Katherine T. Peter.", "authors": "Cwiertny DM et al.", "journal": "Environmental science & technology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41804290/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41781573", "title": "Preventing chick culling in the poultry industry with a new biomarker for rapid in ovo gender screening.", "authors": "Drouin N et al.", "journal": "Scientific reports", "date": "2026 Mar 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41781573/", "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "pubmed", "pmid": "41766677", "title": "Atomic H* Production Amplified by Precisely Tailored Ag-Pt Dual-Atom Synergy: Crucial Roles in 6PPD Detoxification for Water Purification.", "authors": "Xie Y et al.", "journal": "Environmental science & technology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41766677/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41690300", "title": "BRD4-mediated ER membrane contact creates functionally distinct mitochondrial subtypes.", "authors": "Chen B et al.", "journal": "Molecular cell", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41690300/", "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41690203", "title": "Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.", "authors": "Palmieri L et al.", "journal": "Gynecologic oncology", "date": "2026-03-29", "url": "https://pubmed.ncbi.nlm.nih.gov/41690203/", "sentiment": { "label": "negative", "score": -0.202, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41574660", "title": "Validation of Plasma Free Hemoglobin Testing for Extracorporeal Membrane Oxygenation (ECMO) Patients.", "authors": "Asare-Werehene M et al.", "journal": "The journal of applied laboratory medicine", "date": "2026 Mar 5", "url": "https://pubmed.ncbi.nlm.nih.gov/41574660/", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41170836", "title": "Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience.", "authors": "Hlevnjak M et al.", "journal": "International journal of cancer", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41170836/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "reddit", "subreddit": "TopCharacterTropes", "title": "\"I can do really cool badass things, but I am totally unprepared to deal with this ordinary activity.\"", "text": "1. Tony Stark/Iron Man in the \"Avengers Assemble\" Animated TV show: Tony has a friendly bet with Captain America that he can stay off any sort of technology for 24 hours. If he loses, he'll agree to follow Cap's intense gym workout, and if he wins, Cap has to be the test subject for his new invention. Tony immediately is stopped by his Avengers coworkers whenever he tries to use tech for something trivial, like turning on the TV or using the lift, leading him to immediately accept defeat just an", "author": "SatoruGojo232", "score": 4749, "num_comments": 511, "date": "2026-03-23", "url": "https://reddit.com/r/TopCharacterTropes/comments/1s1cve1/i_can_do_really_cool_badass_things_but_i_am/", "sentiment": { "label": "positive", "score": 0.389, "confidence": 0.39 } }, { "source": "reddit", "subreddit": "halo", "title": "Why seems everyone hate the Gen 2 Mjolnir?", "text": "I could never understand the fans' hatred for this iteration of the Mjolnir armor, and I'm quite curious about the subject.\n\nPersonally, I really liked it (it's my favorite version). But what surprises me is that very few people seem to like these design styles.\n\nI like them because they make the Spartans look lighter, more agile, and technologically advanced. Which, narratively speaking, I think makes sense.\n\nCould that be why? That the general public prefers Spartans as super-armored tanks, an", "author": "Prestigious-Meat-750", "score": 1277, "num_comments": 391, "date": "2026-02-27", "url": "https://reddit.com/r/halo/comments/1rgjl5u/why_seems_everyone_hate_the_gen_2_mjolnir/", "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "reddit", "subreddit": "agile", "title": "25 years of agile. The real lesson is changeability", "text": "The best decisions aren't the cheapest or the fastest. They're the ones easiest to change later. It's the most useful thing I've learned from 22 years of practicing agile methodologies.\n\nHey, 25 years since the Agile Manifesto! \n\nWatching the anniversary livestream made me nostalgic. My journey in the agile world started back in 2003 after reading \"Agile Software Development\" by Alistair Cockburn. It was so inspiring that I decided I would try to work in companies that use some agile methodologi", "author": "raydenvm", "score": 24, "num_comments": 32, "date": "2026-03-05", "url": "https://reddit.com/r/agile/comments/1rl9sq4/25_years_of_agile_the_real_lesson_is_changeability/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "Microvast", "title": "Microvast ($MVST): Strategic Agility, Hidden Subsidiaries, and the Table Being Set", "text": "This is the companion piece to my Q4 earnings review (which graded my own preview a D+). The review covered the miss. This covers what’s being built underneath it.\n\nI spent the weekend in the 10-K, Exhibit 21, Chinese business registries, and environmental filings. A few findings that haven’t been discussed anywhere I’ve seen.\n\n—- \n\n**The Ontime construction subsidiary**. \n\nTwo entities hit the subsidiary list for the first time in the FY2024 10-K. Everyone knows about Microvast Technology, LLC ", "author": "Bradydono92", "score": 72, "num_comments": 0, "date": "2026-03-24", "url": "https://reddit.com/r/Microvast/comments/1s22obg/microvast_mvst_strategic_agility_hidden/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "FrenchArmedForces", "title": "The Rafale is a supremely versatile multirole fighter, fast, agile, and lethal, able to dominate air, land, and sea missions with unmatched flexibility and cutting-edge technology.", "text": "", "author": "ForTheGloryOfAmn", "score": 38, "num_comments": 0, "date": "2026-03-18", "url": "https://reddit.com/r/FrenchArmedForces/comments/1rwvrcf/the_rafale_is_a_supremely_versatile_multirole/", "sentiment": { "label": "positive", "score": 0.71, "confidence": 0.71 } }, { "source": "reddit", "subreddit": "StockChats", "title": "$A - Agilent Technologies", "text": "", "author": "Decent_Incident5719", "score": 1, "num_comments": 0, "date": "2026-03-26", "url": "https://reddit.com/r/StockChats/comments/1s4adlj/a_agilent_technologies/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BPOinPH", "title": "WTW Hiring: Junior Scrum Master / Agile Delivery Coordinator", "text": "For a referral, simply DM me your email address and mention this position. I’ll send you a referral link via email, where you can upload your resume.\n\nFor those who have already applied, please check your email regularly, including your spam folder, as some HireVue invites may end up there. Also, check your application status on the website. Note that “Application Submitted” means your application is no longer active. The initial interview invitation may take some time, depending on the required", "author": "yuinrei", "score": 2, "num_comments": 0, "date": "2026-03-21", "url": "https://reddit.com/r/BPOinPH/comments/1rzi5b8/wtw_hiring_junior_scrum_master_agile_delivery/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "edgar_news", "title": "Agilent Technologies, Inc.", "text": "Agilent Technologies, Inc. held its Annual Meeting where stockholders approved amendments to the Certificate of Incorporation and Bylaws, including declassification of the Board over three years. Stockholders voted on director elections, executive compensation, and the appointment of the accounting firm.\n\n*Agilent Technologies, Inc. [A](https://www.google.com/finance/quote/A:NYSE) is headquartered in Santa Clara, CA.*\n\n[Source](https://www.sec.gov/Archives/edgar/data/1090872/000119312526117614/a", "author": "edgar_news_01", "score": 1, "num_comments": 0, "date": "2026-03-20", "url": "https://reddit.com/r/edgar_news/comments/1rz7ij1/agilent_technologies_inc/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "StockChats", "title": "$A - Agilent Technologies", "text": "", "author": "Decent_Incident5719", "score": 1, "num_comments": 0, "date": "2026-03-19", "url": "https://reddit.com/r/StockChats/comments/1ry38nn/a_agilent_technologies/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "menajobs", "title": "Business Analyst (OutSystems / Agile Delivery) at VAM Systems (Manama, Bahrain)", "text": "**VAM Systems** — Manama, Bahrain, 🇧🇭\n\n**Work Model:** On-site \n**Experience:** Mid-level · 5+ years \n**Type:** Full-time \n**Category:** Technology \n**Skills:** Business Analysis, OutSystems, Agile, Scrum, Jira\n\n---\n\n**The opportunity**\n\nSeeking a Business Analyst with 5+ years experience in Agile/Scrum and digital transformation projects using OutSystems.\n\n**Key requirements**\n\n- 5+ years Business Analyst experience\n- Agile/Scrum project exposure\n- Digital transformation project experience\n", "author": "menajobs-bot", "score": 1, "num_comments": 0, "date": "2026-03-16", "url": "https://reddit.com/r/menajobs/comments/1rv2d8y/business_analyst_outsystems_agile_delivery_at_vam/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "ProjectManagerDocs", "title": "Agile, Product & Software Systems", "text": "Introduction: \"The landscape of enterprise product delivery is evolving at breakneck speed. To stay competitive, teams must look beyond basic Scrum and adopt sophisticated Enterprise Agile techniques that align with overarching business goals. The integration of high-level software systems like SAP, PLM, and ERP is no longer optional it is the foundation of modern efficiency.\n\nIn this hub, we explore the intersection of Agile methodology and enterprise technology. We’ve curated a list of deep-di", "author": "PMTemplates1", "score": 3, "num_comments": 1, "date": "2026-03-03", "url": "https://reddit.com/r/ProjectManagerDocs/comments/1rjy5lp/agile_product_software_systems/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "StockChats", "title": "$A - Agilent Technologies", "text": "", "author": "Decent_Incident5719", "score": 1, "num_comments": 0, "date": "2026-03-12", "url": "https://reddit.com/r/StockChats/comments/1rrtkku/a_agilent_technologies/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "edgar_news", "title": "Agilent Technologies, Inc.", "text": "Agilent Technologies announced that Rodney Gonsalves, Vice President, Corporate Controller, and Principal Accounting Officer, will retire in January 2027. His departure isn't due to disagreements.\n\n*Agilent Technologies, Inc. [A](https://www.google.com/finance/quote/A:NYSE) is headquartered in Santa Clara, CA.*\n\n[Source](https://www.sec.gov/Archives/edgar/data/1090872/000119312526096487/a-20260305.htm)", "author": "edgar_news_01", "score": 1, "num_comments": 0, "date": "2026-03-06", "url": "https://reddit.com/r/edgar_news/comments/1rmqxry/agilent_technologies_inc/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "StockChats", "title": "$A - Agilent Technologies", "text": "", "author": "Decent_Incident5719", "score": 1, "num_comments": 0, "date": "2026-03-05", "url": "https://reddit.com/r/StockChats/comments/1rlk9o2/a_agilent_technologies/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "BetterOffline", "title": "I feel like I'm slowly losing my mind", "text": "I'm not using AI, I work in software quality. I write and run manual tests, sometimes automated tests but no code. I have mandatory ojectives on AI usage that I begrudgingly tackled last quarter and I created an agent to analyze documentation and draft test cases. It's shit. It takes forever for me to read through all the output test cases, the bot misses half of the important ones and bloat the output with useless ones. I decided that I would gain more time by doing things myself, never used th", "author": "ConsciousLifeform", "score": 320, "num_comments": 71, "date": "2026-03-17", "url": "https://reddit.com/r/BetterOffline/comments/1rw1nid/i_feel_like_im_slowly_losing_my_mind/", "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "reddit", "subreddit": "HyruleEngineering", "title": "Hyrule ATV — The Best All‑Around 4WD Utility Vehicle Powered by Improved FESCA and the QLW Frame", "text": "The “**Hyrule ATV**” is not built to maximize a single performance metric like top speed. Instead, it is engineered as an **all‑around utility vehicle** that prioritizes **real, everyday usability** throughout your adventure in Hyrule. Its design goal is to deliver top‑tier performance across every capability required for practical travel, resulting in the **ultimate all‑around machine**. This build focuses on all‑around performance for real adventure use, rather than competing with top‑speed‑on", "author": "Exact_Fox_4980", "score": 292, "num_comments": 54, "date": "2026-03-07", "url": "https://reddit.com/r/HyruleEngineering/comments/1rmuj2j/hyrule_atv_the_best_allaround_4wd_utility_vehicle/", "sentiment": { "label": "positive", "score": 0.807, "confidence": 0.81 } }, { "source": "reddit", "subreddit": "ProductManagement_IN", "title": "3+ yrs Product Manager. 150–200 applications in ~3 months, no calls. Resume + positioning feedback?", "text": "Hi everyone, looking for honest, actionable feedback.\n\ni havent been getting any response, having no calls is making me look if i have something wrong with my profile, feedback would be highly appreciated.", "author": "Party-Bell8912", "score": 59, "num_comments": 99, "date": "2026-03-12", "url": "https://reddit.com/r/ProductManagement_IN/comments/1rrpptf/3_yrs_product_manager_150200_applications_in_3/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "reddit", "subreddit": "techcompenso", "title": "Annunciata la classifica Best Workplaces Italia 2026", "text": "Io per esempio conosco Jet HR e a prescindere dal riconoscimento credo siano davvero una bella realtà.\n\nQualcuno che lavora in una di queste aziende?", "author": "flallo95", "score": 111, "num_comments": 75, "date": "2026-03-20", "url": "https://reddit.com/r/techcompenso/comments/1ryw3un/annunciata_la_classifica_best_workplaces_italia/", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "reddit", "subreddit": "SpeculativeEvolution", "title": "Bosun’s Journal: Eyriepeople – Heart of the Swarm – Man after March 06", "text": "Bosun’s Journal, MET: 3,957,910,228,407,931 seconds with a possible deviation of 1 second.\n\nThe second generation of passengers has inhabited the Nebukadnezar for over 2 million years by now. Civilizations rose and fell, new species achieved sapience, and technologies were invented, forgotten and rediscovered over and over. A particularly noteworthy technology is mind control. Interfacing with the brain of a creature to influence or outright control its body movements, emotions and thoughts. The", "author": "CaptainStroon", "score": 465, "num_comments": 29, "date": "2026-03-06", "url": "https://reddit.com/r/SpeculativeEvolution/comments/1rmhsqv/bosuns_journal_eyriepeople_heart_of_the_swarm_man/", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "reddit", "subreddit": "makeyourchoice", "title": "Nrg99hg Gifts of Faves CYOA Obscure Video Games Waifus Edition v2", "text": "Link: [https://imgchest.com/p/o24amremd4l](https://imgchest.com/p/o24amremd4l)\n\n**Note: for anyone wanting to play Oni the PC version is better than the PS2 port and use the anniversary edition patch so it can run on modern PC.**\n\n**For the Remember Me game there was a bug in Madame Boss Fight during the falling scene because the Quick Time Event doesn't work, I don't remember how I fixed it, so if you are stuck just look through guides or discussions.**\n\n**But after years they should have fixed", "author": "Nrg99hg", "score": 171, "num_comments": 44, "date": "2026-03-23", "url": "https://reddit.com/r/makeyourchoice/comments/1s1jh33/nrg99hg_gifts_of_faves_cyoa_obscure_video_games/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "makeyourchoice", "title": "Nrg99hg Gifts of Faves CYOA Obscure Video Games Waifus Edition v1", "text": "link: [https://imgchest.com/p/na7knbr9378](https://imgchest.com/p/na7knbr9378)", "author": "Nrg99hg", "score": 233, "num_comments": 32, "date": "2026-03-21", "url": "https://reddit.com/r/makeyourchoice/comments/1rztw1t/nrg99hg_gifts_of_faves_cyoa_obscure_video_games/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "reddit", "subreddit": "microsaas", "title": "2 weeks after going live with the premium tier, and I have 19 paying users and a user inspired UI improvement.", "text": "About two weeks ago, I launched the Premium tier of [Stock Taper](https://www.stocktaper.com/).\n\nHappy to say I finally have paying users. I’m at 19 total so far, and three of them chose the annual plan, which feels amazing.\n\nIs 19 anything to write home about? Not really. But symbolically it means a lot. It tells me there’s value here, and I should keep pushing on marketing. The problem is my marketing efforts are not great right now. I’ve been relying too heavily on promo friendly subreddits t", "author": "wombatGroomer", "score": 87, "num_comments": 59, "date": "2026-02-27", "url": "https://reddit.com/r/microsaas/comments/1rgc1gq/2_weeks_after_going_live_with_the_premium_tier/", "sentiment": { "label": "positive", "score": 0.735, "confidence": 0.74 } }, { "source": "reddit", "subreddit": "makeyourchoice", "title": "Nrg99hg Gifts of Faves CYOA Obscure Video Games: Gamer & Waifus Edition v1", "text": "Link: [https://imgchest.com/p/ne7b38xwgy5](https://imgchest.com/p/ne7b38xwgy5)\n\nHere is another obscure video game gift of faves.\n\nI tried to add some more sci-fi and shooter games to the list. I am more of a fantasy guy, but I do play some that look interesting or one that I pick randomly to play when I am bored, and I find some that I enjoy.\n\nNote: to this day I have never played or touched any of Call of Duty, Battlefield, or even Halo games despite playing many bad shooter games that I picke", "author": "Nrg99hg", "score": 135, "num_comments": 42, "date": "2026-03-26", "url": "https://reddit.com/r/makeyourchoice/comments/1s4k6br/nrg99hg_gifts_of_faves_cyoa_obscure_video_games/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } } ] } }